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INTRODUCTION
The hepatitis D virus (HDV) is a defective RNA-virus which
depends on the hepatitis B virus (HBV) for replication. HDV
is able to replicate in hepatocytes without the help of HBV,
producing HDV RNA and HDAg, but assembly of the viral
particle and survival outside hepatocytes require HBsAg.
HDV infection is often severe and when it causes a super-
infection of hepatitis B, deterioration of the liver disease often
occurs. Chronic hepatitis D infection leads to cirrhosis in
70% of patients [1].
The only effective treatment for HBV-infection is inter-
feron alpha (IFN) and HBeAg-seroconversion occurs in
approximately 33% of patients [2]. Lamivudine, an oral
nucleoside analogue, has been shown to cause suppression
of HBV DNA, a marker of active viral replication, in up to
80% of patients after 6 months of therapy [3]. Quanti-
tative HBsAg concentrations also decreased during treat-
ment. However, after withdrawal of this drug, an
immediate rise in HBV DNA to pretreatment levels was
observed followed by a more gradual increase in HBsAg
concentrations [3].
Abbreviations: HDV, hepatitis D virus; HBV, hepatitis B virus;
IFN, interferon alpha.
Correspondence: Dr R. A. de Man, Department of Hepatogastro-
enterology, University Hospital Rotterdam, PO Box 2040, 3000 CA
Rotterdam, The Netherlands.
Journal of Viral Hepatitis, 2000, 7, 428–434
Ó 2000 Blackwell Science Ltd
SUMMARY. Currently, the best option for patients with
hepatitis delta is interferon alpha therapy for at least one
year. To evaluate the effect of the combination lamivudine–
high-dose interferon alpha therapy, we first treated eight
patients with chronic hepatitis delta infection with lamivu-
dine for at least 24 weeks; then lamivudine was combined
with a high dose of interferon alpha followed by a regular
dose (9 MU tiw). Follow-up was 12 weeks. Virological, bio-
chemical and histological features were evaluated for
response to therapy. At baseline, all patients were HBsAg
positive in serum and HDV RNA-(PCR)positive in plasma;
HBV DNA was undetectable with the Digene Hybrid Capture
assay (limit of detection 1.5 · 106 geq ml–1) in all cases.
Transaminases were elevated in all patients; median ALT 68
(range 48–143) IU l–1. Seven of eight patients completed the
course; one patient with a pre-existing sickle cell trait was
withdrawn from the trial due to the development of a
nephrotic syndrome. The HBsAg-concentration in serum
decreased in two out of seven patients (29%). However, there
was no significant decrease in the HBsAg-concentration
in serum during treatment (median 3654 PEU l–1 (range
548–7684) to 5300 PEU l–1 (range 168–19639)). The drop
of HDV RNA in plasma from baseline during treatment was
not significant. Decrease of HDV RNA was observed in three
out of seven patients (43%) (median 105 geq ml–1; range
103–106 to median 103 geq ml–1; range 102–107). Serum
ALT did not change as reflected by a median of 68 IU l–1
(range 48–143) at start of therapy to 63 IU l–1 (range
20–171) at the end of therapy. At the end of treatment
transaminases had normalised in one patient and decreased
in three other patients (improvement in 57%). However,
three of these four patients showed a rebound after with-
drawal of therapy. The Histology Activity Index (HAI)
indicated a drop from a median score of 7 (range 5–9) at
baseline to 5 (range 3–8) at the end of treatment, but an
increase in fibrosis from a median grade of 2 (range 1–3) at
baseline to 3 (range 1–4) at the end of treatment was
observed. In conclusion, this study does not yield support for
the combination of an HBV suppressor and 16 weeks of
high-dose interferon for therapy aimed at eradicating the
hepatitis delta virus.
Keywords: chronic hepatitis B, hepatitis delta, lamivudine,
interferon alpha.
IFN is the most promising agent for the treatment of
chronic hepatitis D (HDV). Most studies stress the import-
ance of prolonging therapy and increasing the dose,
frequency and duration of administration of interferon
[4–9].
A pilot study demonstrated the lack of efficacy of lami-
vudine monotherapy in HDV infection [10] but no data are
available on the safety and efficacy of lamivudine–IFN
combination therapy for patients with HDV. Therefore, we
performed a pilot study in which we pretreated eight patients
with lamivudine to reduce HBsAg, followed by high doses of
IFN in combination with lamivudine.
PATIENTS AND METHODS
All chronic HDV-infected patients who visited the outpatient
clinic of the University Hospital Rotterdam from the first of
January 1996 until the first of January 1998 were consid-
ered eligible. The study was approved by the Medical Ethics
Committee of the University Hospital Rotterdam.
Patients could be included in the study if they were HBsAg
positive in serum and HDV RNA-positive by PCR in plasma
and if the liver biopsy was positive for HDAg. ALT and AST at
screening had to exceed the upper limit of normal (30 IU l–1).
All patients received 100 mg lamivudine od for at least
24 weeks. Subsequently, IFN (Roferon, Roche) was added:
first at a high dose of 9 MU od for four weeks, followed by
9 MU tiw for 12 weeks. Both IFN and lamivudine were
withdrawn after at least 16 weeks of combination therapy.
Follow-up was 12 weeks.
A liver biopsy was taken prior to the start of lamivudine
therapy and at the end of combination therapy. All liver
biopsies were graded according to the Histology Activity
Index (HAI) using the Desmet modification of the Knodell
scoring system [11,12]. The specimens were also stained
immunohistochemically to detect surface antigen of the
hepatitis B virus and hepatitis delta antigen, as previously
described [13]. The histological diagnosis was made by two
independent histopathologists according to international
criteria [14].
Blood samples were drawn every four weeks during treat-
ment and follow-up. Serum samples were stored at –20 °C
for detection of HBsAg and HBV DNA, plasma samples were
stored at –80 °C for detection of HDV RNA. Haematological
parameters, markers of hepatitis activity (ALT, AST) and
bilirubin levels were determined every four weeks.
HBsAg was quantified with a microparticle enzyme
immunoassay (MEIA, AxSYM, Abbott) against a standard
related to the HBsAg reference preparation (Paul Ehrlich
Institute). HBV DNA levels were measured with a Hybrid
Capture assay (Digene, Abbott, UK) quantified with the
EUROHEP standard as reference and expressed in genome
equivalents ml–1 (geq ml–1). The limit of detection of this
assay is 1.5 · 106 geq ml–1. HBeAg was detected with the
IMx-assay (Abbott, Chicago, USA). HDV RNA was quantified
by means of a PCR method, as described by de Man et al.
[13], with a limit of detection of 100 geq ml–1.
Virological response to therapy
A complete virological response was defined as disap-
pearance of HDV RNA in serum. A partial response was
defined as a reduction in HDV RNA from baseline. The
decrease in HBsAg concentration in individual patients
was monitored during therapy and follow-up. In the liver,
a response was defined by a decrease in the number of
hepatocytes with a positive stain for hepatitis B and D
antigens.
Biochemical response to therapy
A complete biochemical response was defined as normal-
ization of serum ALT, a partial response as a reduction of
ALT with respect to baseline values.
Histological response to therapy
A histological response was defined by a decrease in
inflammation and fibrosis.
Statistical analysis
Patients were evaluated in the per protocol analysis if they
completed at least 24 weeks of lamivudine monotherapy
followed by at least 16 weeks of IFN therapy, initially at high
doses.
The Wilcoxon’s sign rank test was used to analyse viro-
logical, biochemical and histological changes in these
patients.
RESULTS
Eight patients were included in this trial. In patient 8, lam-
ivudine and IFN were discontinued after 3 weeks of combi-
nation therapy due to a nephrotic syndrome which required
hospitalization. This patient was excluded from the per
protocol analysis.
Five patients were found to be negative for antibodies to
the human immunodeficiency virus (HIV); anti-HIV was not
determined in patients 2, 3 and 4. Seven patients were
negative for antibodies against the hepatitis C virus (HCV).
Anti-HCV was found to be positive in patient 4; however,
HCV RNA by PCR was negative in this patient.
The median age of the treated group was 38 (range
25–39) years at the start of lamivudine treatment. Patient
characteristics are presented in Table 1.
Baseline characteristics are shown in Table 2. All patients
were positive for HBsAg in serum. None of the patients had
an active hepatitis B infection, as shown by the negative
hybridization assay for HBV DNA and HBeAg negativity for
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all patients. All patients were positive for HDV RNA in
plasma with a positive stain of the liver biopsy for HDAg.
None of the patients had cirrhosis before the start of therapy.
The median HAI score for disease activity was 7 (range 5–9)
at the start of therapy. All patients had elevated transam-
inase levels (< 5 · ULN).
The following results are based on the patients included in
the per protocol analysis. The median time elapsed from
pretreatment biopsy to post-treatment biopsy was 15 (range
12–30) months. The median duration of lamivudine treat-
ment before administration of IFN was 8 (range 5.5–10.5)
months followed by a median period of 4 (range 4–6)
months of combination therapy with IFN. Patient 4 con-
tinued on lamivudine therapy for another 6 months after
withdrawal of IFN.
Virological response
There was no significant change in HDV RNA levels between
the start and the end of treatment. A decrease from a median
of 105 geq ml–1 (range 103–106 geq ml–1) to a median of
103 geq ml–1 (range 102–107 geq ml–1) was observed. At
the end of treatment, a complete virological response with
regard to HDV RNA was not found for any of the patients.
A partial response was found in patients 3, 5 and 6 with a
decrease in hepatitis D viral load of 1log, 3log and 3log,
respectively.
HBsAg increased slightly from a median of 3654 (range
548–7684) PEU l–1 to 6911 (range 358–17523) at the
start of IFN therapy and subsequently decreased to 5300
(range 168–19639) PEU l–1 at the end of therapy.
Patients 3 and 6 showed a marked decrease of 45% (at
start of IFN therapy) to 69% (at the end of therapy) and
19% (at start of IFN therapy) to 54% (at the end of
therapy), respectively. Patient 3 underwent a rebound
after withdrawal of therapy whereas the level in patient 6
continued to decrease with respect to the end of therapy
level (Table 3).
HBV DNA was not used as a marker of response to ther-
apy, since it was suppressed below the limit of detection
of the liquid hybridization assay in all cases. In four
Table 1 Patient characteristics
Median age (range) 38 (25–41)
Sex (m/f ) 6/2
Route of transmission of HBV/HDV
Intravenous drug abuse 1
Sexual 1
Unknown 6
Country of birth
The Netherlands 1
Africa 4
Middle East 3
Table 2 Baseline characteristics
HBsAg*
HDV RNA
PCR  ALTà
Patient (PEU l–1) (geq ml–1) (IU l–1) HAI§ Fibrosis–
1 3654 105 51 7 2
2 6629 105 113 9 3
3 548 104 129 6 3
4 3622 106 68 5 1
5 5999 106 143 8 2
6 736 105 48 7 3
7 7684 105 65 5 1
8 170 104 50 3 1
* Limit of detection = 0.6 PEU l–1.
  Limit of detection = 100 geq ml–1.
à Upper limit of normal = 30 IU l–1.
§ HAI = Histology Activity Index (range 0–18).
– Range 0–4; 4 indicates cirrhosis.
HBsAg HDV RNA
ALT (IU l–1)
Serum Liver Serum Liver ULN = 30 IU l–1 HAI Fibrosis
pt 1 ›45% fl » fl 51fi171 fl(2) ›(2)
pt 2 ›196% » ›2log » 13fi50 fl(4) »
pt 3 fl69% » fl1log fl 129fi20 fl(3) »
pt 4 » fl ›1log » 68fi63 ›(3) ›(1)
pt 5 ›20% » fl3log fl 143fi98 » ›(1)
pt 6 fl54% » fl3log fl 48fi68 fl(2) fl(2)
pt 7 ›96% › » » 65fi53 ›(2) ›(2)
fl, decrease; », no change; ›, increase; HAI, Histology Activity Index; ( ), number
of points increase/decrease; ULN, Upper Limit of Normal.
Table 3 Per protocol analysis of
response to therapy (baseline vs. end of
combination therapy)
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out of seven patients HBV DNA was even suppressed
below the limit of the sensitive PCR-test (limit of detection
400 geq ml–1).
Biochemical response
No significant change was observed between the start and
the end of treatment (P  0.499) (Fig. 1). Median ALT
remained at the same level before, during and after ther-
apy. The median ALT at start of lamivudine therapy was
68 IU l–1 (range 48–143), 74 IU l–1 (range 44–107) at
the moment of addition of IFN therapy, 63 IU l–1 (range
20–171) at the end of therapy and 68 IU l–1 (range
19–293) at the end of follow-up. Patient 3 exhibited a
complete biochemical response, combined with a decrease in
HDV RNA and HBsAg (Fig. 2). Patients 2, 5 and 7 showed a
partial response with a decrease in transaminase levels from
113, 143 and 65 IU l–1 at the start of therapy to 50, 98,
53 IU l–1 at the end of treatment, respectively. However, in
three patients, including the patient with a complete
response, a rebound occurred during follow-up. ALT
remained at the same level or increased during treatment in
the other three patients (Table 3).
Histology
Comparison of biopsies taken at the start and the end of
treatment revealed an improvement in the overall HAI-score
from a median of 7 (range 5–9) to 5 (range 3–8) (P  0.395,
n.s.). There was an increase in the median rate of fibrosis
from grade 2 (range 1–3) at the start of treatment to grade 3
(range 1–4) at the end of treatment (P  0.334, n.s). Two
patients developed cirrhosis during treatment. Staining of
biopsies for HBsAg showed a drop in the median from 5%
(range 0–50%) to 1% (range 0–30%). HDAg staining was
minimal in all cases, both at the start (median 1%, range
1–10%) and at the end of therapy (median 1%, range 0–1%)
(Table 3).
Adverse events
Combination therapy was discontinued for patient 8 due to a
nephrotic syndrome. After 3 weeks of high dose IFN, this
patient had to be hospitalised. The patient had already been
diagnosed with a b-thalassaemia, a heterozygous sickle cell
trait and hypertension. A kidney biopsy showed sclerosis of
the glomeruli, caused by ischaemic damage induced by
Fig. 1 Response of (a) ALT and (b) AST during therapy, individual patients. Upper limit of normal  30 IU l–1.
Ó 2000 Blackwell Science Ltd, Journal of Viral Hepatitis, 7, 428–434
Lamivudine–high dose interferon for hepatitis D infection 431
sickle cell crises in the past. Moreover, necrosis of tubuli was
observed, probably caused by IFN. After withdrawal of both
lamivudine and IFN, renal function improved as did the
clinical signs. This case resembles previous case reports on
renal toxicity due to the use of IFN [15,16].
Lamivudine monotherapy was well tolerated. Five of seven
patients experienced mild side-effects during lamivudine–IFN
combination therapy, related to the IFN (flu-like symptoms,
hair loss, fatigue).
DISCUSSION
Since chronic hepatitis D patients are at high risk of devel-
oping liver cirrhosis, they are in need of effective antiviral
therapy to prevent liver decompensation. In our study, we
combined our knowledge about lamivudine treatment for
chronic hepatitis B patients and IFN therapy for chronic
hepatitis delta patients. This resulted in initially high-dose
IFN treatment combined with a suppressor of active repli-
cation of the hepatitis B virus: lamivudine.
The focus of this treatment was the virological response to
therapy as shown by changes in quantitative HDV RNA and
quantitative HBsAg, the biochemical response as shown by
changes in ALT and the possible histological improvement.
No significant changes in HDV RNA were seen in
response to treatment, nor did any of the patients show a
complete virological response. However, a decrease was
seen in three out of seven patients. This observation does
not show the same results as a study published by Farci
et al. [9] in which high-dose IFN (9 MU tiw) during
48 weeks caused a complete virological response in the
majority of patients at the end of treatment. The poorer
results can at least partly be explained by the considerable
shorter treatment period applied in our study. Studies in
which patients were treated with induction of IFN followed
by lower doses during one year, have produced inconsistent
results. A multicentre Italian trial did not show a signifi-
cantly stronger suppression of HDV RNA compared to the
placebo [4], whereas a French trial showed a complete
response of HDV RNA at the end of treatment in seven out
of nine treated patients [5]. The differences as seen in these
trials might have been caused by the different ethnic
backgrounds of those patients infected with more suscept-
ible strands of virus or because of the shorter duration of
infection at the start of treatment.
Since HDV is said to disappear from serum after HBsAg
seroconversion [17], HBV as a prerequisite for HDV survival
should be the main focus of treatment.
Fig. 2 Response of HBsAg, HDV RNA and ALT during therapy in patient 3 who exhibited a decrease in viral load.
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HBsAg did not change significantly during treatment of
our patients. A reduction was observed in two patients which
coincided with a normalization of ALT in one patient and a
decrease in ALT in the other patient. In the patient with a
complete biochemical response, HDV RNA in plasma, HDAg
in the liver and the HAI score decreased as well. Lamivudine
as therapy for chronic hepatitis B monoinfection has been
studied extensively and has proved to be a suppressor of HBV
DNA [3,18,19]; also, a reduction of HBsAg which followed
the decrease in HBV DNA was observed during a 6-month
treatment period [3]. A recent study in which five hepatitis
delta patients were treated with lamivudine for 52 weeks and
followed for 6 months after withdrawal of therapy showed a
decrease in HBsAg and HDV RNA PCR in only one HBeAg
positive patient. No improvement was seen in either liver
histology or serum transaminase activity [10]. Lamivudine is
a suppressor of reverse transcription from a positive RNA
strand to – in the case of the hepatitis B virus – a negative
DNA strand. The hepatitis D virus, however, is a negative
RNA virus which replicates without reverse transcription.
Moreover, the hepatitis D virus is dependent on cellular
polymerases, probably RNA polymerase II, for replication.
Lamivudine has little effect on a-, b- and c-polymerases of
mammalian cells. Therefore, it is not to be expected that
lamivudine would have any effect on replication of the hep-
atitis D virus. As a result, lamivudine could only have an
indirect effect on the hepatitis D virus by reducing HBsAg. As
can be observed in our patient group, reduction of HBsAg in
serum in two patients coincided with a reduction of HDV
RNA in plasma in both patients.
A complete biochemical response was observed in one
patient and a partial response was seen in three patients at
the end of treatment. However, IFN treatment for up to one
year caused normalization of transaminases in the majority
of patients when higher doses were given [9]. As described
during lamivudine therapy for chronic hepatitis B, inflam-
mation was reduced during a 6-month treatment period. In
these patients, the decrease in transaminases followed a
decrease in HBV DNA as marker of active viral replication.
As shown by Lai et al. [19], lamivudine therapy for chronic
hepatitis B patients caused normalization of ALT in the
majority of cases after one year of treatment compared to
the placebo group. In the patients in our study, however, the
hepatitis B virus was suppressed, as shown by HBeAg neg-
ativity and HBV DNA negativity by PCR in four out of seven
patients and by liquid hybridization assay in the other three
patients. As described by others [20], the inactivity of the
hepatitis B virus is probably caused by the hepatitis D virus.
The low level of hepatitis B replication suggests that the
elevation of transaminases seen in all patients at the start of
therapy was probably caused by the hepatitis D virus. The
relatively mild inflammation observed in these patients at the
start of therapy contradicts data published by others [4,5,9].
One reason for this less severe inflammation could be that
these patients, predominantly originating from African
countries, were infected with less virulent genotypes [21].
Furthermore, a fluctuating course of the disease should be
taken into consideration: most of our patients may have been
in a relatively quiet phase at the moment of entry. Moreover,
these patients could have suffered from a more advanced
disease in which a more stable, lower level of inflammation,
reflected in slightly increased transaminases, was achieved.
A two-point, not significant, drop in HAI was observed. In
contrast, an increase in fibrosis occurred. Changes in the
number of hepatocytes infected with virus, as indicated by
staining of hepatitis B and D antigens, were ambiguous. In
addition, disappearance of HDAg staining in three patients
contrasted with HDV RNA in plasma, which was still
detectable. The absence of HDAg in the liver might have
been caused by sampling, with relatively few hepatocytes
expressing delta antigen.
Although some patients experienced a short-term decrease
in viral load and/or ALT, a complete virological response in
combination with a complete biochemical response was not
observed.
In conclusion, neither lamivudine alone nor the addition
of initially high-dose IFN was capable of significantly
reducing HDV RNA, HBsAg, serum transaminases or
histology. On the basis of our data we cannot recommend
lamivudine–IFN combination therapy for chronic HDV
infection.
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